Latest Gilead Sciences News & Updates

See the latest news and media coverage for Gilead. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Gilead Sciences (Gilead)

Biopharmaceutical company focused on virology, oncology and inflammation

gilead.com
Headquarters
Foster City, United States
Founded year
1987
Company type
Public company
Number of employees
10,000+

Last updated

Latest news about Gilead Sciences (Gilead)

In short: Gilead Sciences aggressively expanded its oncology and autoimmune portfolios through multibillion-dollar acquisitions and HIV therapy advancements.

Company announcements

  • Gilead

    Gilead announces Q1 2026 financial results

    Revenues rise 4% to $7.0B with HIV sales up 10%. Raises full-year guidance. Completes Arcellx acquisition.

  • Gilead

    FDA grants priority review to Gilead's BIC/LEN HIV treatment

    The once-daily single-tablet regimen targets virologically suppressed adults. PDUFA date is August 27, 2026. Supported by Phase 3 ARTISTRY trials showing efficacy and safety.

  • Gilead

    Gilead completes acquisition of Arcellx

    The deal, valued at $7.8 billion, gives full control of anito-cel for multiple myeloma ahead of potential launch. Arcellx becomes a wholly owned subsidiary.

  • Gilead

    Gilead receives all regulatory approvals for Arcellx acquisition

    Gilead extends tender offer expiration to April 27, 2026. The offer price remains $115 per share plus a $5 CVR contingent on future sales.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Gilead

Track Gilead and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gilead competitors & trending companies

Browse news for competitors to Gilead and other trending companies.